Key Laboratory of Advanced Drug Delivery Systems of Zhejiang Province, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Department of Medical Oncology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
J Control Release. 2023 Jan;353:875-888. doi: 10.1016/j.jconrel.2022.11.041. Epub 2022 Dec 19.
Adoptive cell therapy (ACT) that leverages allogeneic or autologous immune cells holds vast promise in targeted cancer therapy. Despite the tremendous success of ACT in treating hematopoietic malignancies, its efficacy is limited in eradicating solid tumors via intravenous infusion of immune cells. With the extending technology of cancer immunotherapy, novel delivery strategies have been explored to improve the therapeutic potency of adoptively transferred cells for solid tumor treatment by innovating the administration route, maintaining the cell viability, and normalizing the tumor microenvironment. In this review, a variety of devices for cell delivery are summarized. Perspectives and challenges of cell delivery devices for cancer immunotherapy are also discussed.
过继细胞疗法（ACT）利用异体或自体免疫细胞在靶向癌症治疗方面具有广阔的前景。尽管 ACT 在治疗血液恶性肿瘤方面取得了巨大成功，但通过静脉输注免疫细胞来消除实体瘤的效果有限。随着癌症免疫疗法技术的不断发展，人们已经探索了新的输送策略，通过创新给药途径、维持细胞活力和使肿瘤微环境正常化来提高过继转移细胞治疗实体瘤的疗效。在这篇综述中，总结了各种用于细胞输送的装置。还讨论了用于癌症免疫治疗的细胞输送装置的观点和挑战。
